You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR FLUVASTATIN SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for FLUVASTATIN SODIUM

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00199927 ↗ Statins in Proteinuric Nephropathies Completed Mario Negri Institute for Pharmacological Research Phase 3 2003-03-01 End stage renal disease (ESRD) is rapidly growing worldwide. Patients with ESRD have increased morbidity and mortality mostly because of a dramatic excess of cardiovascular disease. Thus, preventing or limiting the progression of chronic nephropathies, in addition to limit the incidence of ESRD, may also postpone death. Drugs that inhibit the renin angiotensin system, such as Angiotensin-Converting-Enzyme inhibitors (ACEi) and Angiotensin II receptor antagonists (ATA), are reno- and cardio-protective in the long-term. There are data that statins,in addition to limit cardiovascular events may have specific reno-protective properties. Thus we designed a study aimed to evaluate whether statins associated to ACEi and ATA may have an additional reno-protective effect. ESPLANADE is a multicenter, prospective, randomized, parallel group study in which, after 2 months treatment with ACEi and ATA, two groups of 90 patients, with or without type 2 diabetes, are randomized to 6 months Fluvastatin (40 or 80 mg/day) treatment YES or NO.Twenty Italian Nephrology Units are involved in the trial. The study is fully coordinated by the Clinical Research Center for Rare Disease Aldo e Cele Daccò, Villa Camozzi, Ranica.
NCT00382161 ↗ Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors Withdrawn Novartis Phase 3 2006-10-01 The purpose of the study is to determine the effect of fluvastatin on penile arterial blood flow and erectile function in patients with arteriogenic ED and cardiovascular risk factors.
NCT00382161 ↗ Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors Withdrawn University Hospital, Saarland Phase 3 2006-10-01 The purpose of the study is to determine the effect of fluvastatin on penile arterial blood flow and erectile function in patients with arteriogenic ED and cardiovascular risk factors.
NCT00416403 ↗ Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Completed National Cancer Institute (NCI) Phase 2 2006-07-01 RATIONALE: Collecting samples of blood and tissue from patients with cancer to study in the laboratory may help doctors learn how fluvastatin effects biomarkers related to breast cancer. PURPOSE: This randomized phase II trial is studying how fluvastatin effects biomarkers in women undergoing surgery for ductal carcinoma in situ or stage I breast cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for FLUVASTATIN SODIUM

Condition Name

Condition Name for FLUVASTATIN SODIUM
Intervention Trials
Breast Cancer 1
Chronic Nephropathy 1
Hypertension 1
Impotence 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for FLUVASTATIN SODIUM
Intervention Trials
Dyslipidemias 1
Proteinuria 1
Carcinoma, Intraductal, Noninfiltrating 1
Kidney Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for FLUVASTATIN SODIUM

Trials by Country

Trials by Country for FLUVASTATIN SODIUM
Location Trials
Italy 7
United States 4
China 1
Germany 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for FLUVASTATIN SODIUM
Location Trials
New York 1
Massachusetts 1
Illinois 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for FLUVASTATIN SODIUM

Clinical Trial Phase

Clinical Trial Phase for FLUVASTATIN SODIUM
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for FLUVASTATIN SODIUM
Clinical Trial Phase Trials
Completed 4
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for FLUVASTATIN SODIUM

Sponsor Name

Sponsor Name for FLUVASTATIN SODIUM
Sponsor Trials
Mario Negri Institute for Pharmacological Research 1
Novartis 1
University Hospital, Saarland 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for FLUVASTATIN SODIUM
Sponsor Trials
Other 5
Industry 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.